



## Sample Information

**Patient Name:** 郭華達

**Gender:** Male

**ID No.:** A122572855

**History No.:** 44798438

**Age:** 57

**Ordering Doctor:** DOC2307C 林育如

**Ordering REQ.:** 0BANBAK

**Signing in Date:** 2021/01/06

**Path No.:** S110-98017

**MP No.:** TM21001

**Assay:** Oncomine Tumor Mutation Load Assay

**Sample Type:** FFPE

**Block No.:** S109-64455A

**Percentage of tumor cells:** 60%

**Note:**

## Sample Cancer Type: Colorectal Cancer

Table of Contents	Page
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2
Biomarker Descriptions	3
Relevant Therapy Summary	5
Relevant Therapy Details	6
Clinical Trials Summary	11

### Report Highlights

2 Relevant Biomarkers  
4 Therapies Available  
18 Clinical Trials

## Relevant Colorectal Cancer Variants

Gene	Finding
BRAF	Not detected
KRAS	Not detected
NRAS	Not detected
NTRK1	Not detected
NTRK3	Not detected



## Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	<i>TP53</i> p.(R273H) c.818G>A tumor protein p53 Allele Fraction: 0.899	None	olaparib	8
	<i>Tumor Mutational Burden</i> 7.62 Mut/Mb measured	<b>pembrolizumab</b> <sup>1</sup>	ipilimumab + nivolumab nivolumab pembrolizumab	12

Public data sources included in relevant therapies: FDA1, NCCN, EMA2, ESMO

**Tier Reference:** Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Although no fusion transcript can be detected, there is high imbalance of the number of 3' reads and 5' reads in the RET gene (3'/5' imbalance value: 25.86). A high 3'/5' imbalance value is suggestive of the presence of gene fusion. The possibility of RET fusion involving partners other than those targeted by the panel cannot be excluded. Further confirmation with other methodologies is suggested.

## Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants								
Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Fraction	Transcript	Variant Effect	Coverage
TP53	p.(R273H)	c.818G>A	COSM10660	chr17:7577120	0.899	NM_000546.5	missense	2000
ARID1A	p.(G1254S)	c.3760G>A	.	chr1:27099881	0.502	NM_006015.5	missense	1087
JUN	p.(E303fs)	c.907delG	.	chr1:59247835	0.309	NM_002228.3	frameshift Deletion	1988
JAK1	p.(=)	c.2220C>T	.	chr1:65310468	0.521	NM_002227.3	synonymous	1995
NTRK1	p.(V99M)	c.295G>A	.	chr1:156834527	0.644	NM_002529.3	missense	1998
PMS1	p.(=)	c.654T>C	.	chr2:190708761	0.043	NM_000534.4	synonymous	599
PAX3	p.(=)	c.807C>T	.	chr2:223086092	0.322	NM_181459.3	synonymous	2000
FANCD2	p.(R328Q)	c.983G>A	.	chr3:10084828	0.353	NM_033084.4	missense	1019
FANCD2	p.(S455G)	c.1363A>G	.	chr3:10089685	0.366	NM_033084.4	missense	1997
ITGA9	p.(G267V)	c.800G>T	.	chr3:37547548	0.071	NM_002207.2	missense	1999
LTF	p.(R23dup)	c.68_69insAAG	.	chr3:46501284	1.000	NM_002343.5	nonframeshift Insertion	1917
EPHA3	p.(E150D)	c.450A>C	.	chr3:89259306	0.349	NM_005233.5	missense	621
PDGFRA	p.(=)	c.1701A>G	.	chr4:55141055	0.999	NM_006206.5	synonymous	1714
APC	p.(Q1328*)	c.3982C>T	.	chr5:112175273	0.889	NM_000038.5	nonsense	1579
FGFR4	p.(R483H)	c.1448G>A	.	chr5:176520705	0.933	NM_213647.2	missense	1998
NOTCH4	p.(L13_L16del)	c.36_47delGCTGCTG CTGCT	.	chr6:32191658	0.211	NM_004557.3	nonframeshift Deletion	
DAXX	p.(E469del)	c.1406_1408delAGG	.	chr6:33287880	0.327	NM_001141970.1	nonframeshift Deletion	608



## Variants (Exclude variant in Taiwan BioBank with >1% allele frequency) (continued)

### DNA Sequence Variants (continued)

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Fraction	Transcript	Variant Effect	Coverage
EPHA7	p.(E636fs)	c.1906_1907insG	.	chr6:93969089	0.629	NM_004440.3	frameshift Insertion	1130
TNFAIP3	p.(E781*)	c.2341G>T	.	chr6:138202424	0.207	NM_001270507.1	nonsense	1468
SYNE1	p.(L5015M)	c.15043T>A	.	chr6:152647681	1.000	NM_182961.3	missense	951
AKAP9	p.(D3011N)	c.9031G>A	.	chr7:91715548	0.322	NM_005751.4	missense	149
TRRAP	p.(=)	c.5787G>A	.	chr7:98552798	0.679	NM_001244580.1	synonymous	841
PIK3CG	p.(=)	c.546C>T	.	chr7:106508552	0.342	NM_002649.3	synonymous	2000
KMT2C	p.(K3793fs)	c.11379delA	.	chr7:151859282	0.261	NM_170606.2	frameshift Deletion	1983
KMT2C	p.(Q3792K)	c.11374C>A	.	chr7:151859288	0.732	NM_170606.2	missense	1983
TAF1L	p.(R1442Q)	c.4325G>A	.	chr9:32631253	0.042	NM_153809.2	missense	118
PTCH1	p.(R893H)	c.2678G>A	.	chr9:98224163	0.243	NM_000264.3	missense	1999
TSC1	p.(S457R)	c.1369A>C	.	chr9:135782187	0.766	NM_000368.4	missense	1995
KMT2A	p.(=)	c.11391T>C	.	chr11:118390741	0.971	NM_001197104.1	synonymous	102
EP400	p.(=)	c.9240G>A	.	chr12:132562086	0.802	NM_015409.4	synonymous	823
LAMP1	p.(P214S)	c.640C>T	.	chr13:113973861	0.115	NM_005561.3	missense	672
TCF3	p.(G431S)	c.1291_1293delGGCinsAGT	.	chr19:1619348	0.981	NM_001136139.3	missense	585
MN1	p.(Q542H)	c.1626A>C	.	chr22:28194906	0.041	NM_002430.2	missense	146
KDM5C	p.(P1324A)	c.3970C>G	.	chrX:53223389	0.783	NM_004187.3	missense	598

## Biomarker Descriptions

### TP53 (tumor protein p53)

**Background:** The TP53 gene encodes the p53 tumor suppressor protein that binds to DNA and activates transcription in response to diverse cellular stresses to induce cell cycle arrest, apoptosis, or DNA repair. In unstressed cells, TP53 is kept inactive by targeted degradation via MDM2, a substrate recognition factor for ubiquitin-dependent proteolysis. Alterations in TP53 is required for oncogenesis as they result in loss of protein function and gain of transforming potential<sup>1</sup>. Germline mutations in TP53 are the underlying cause of Li-Fraumeni syndrome, a complex hereditary cancer predisposition disorder associated with early-onset cancers<sup>2,3</sup>.

**Alterations and prevalence:** TP53 is the most frequently mutated gene in the cancer genome with approximately half of all cancers experiencing TP53 mutations. Ovarian, head and neck, esophageal, and lung squamous cancers have particularly high TP53 mutation rates (60-90%)<sup>4,5,6,7,8,9</sup>. Approximately two-thirds of TP53 mutations are missense mutations and several recurrent missense mutations are common including substitutions at codons R158, R175, R248, R273, and R282<sup>4,5</sup>. Invariably, recurrent missense mutations in TP53 inactivate its ability to bind DNA and activate transcription of target genes<sup>10,11,12,13</sup>.



## Biomarker Descriptions (continued)

**Potential relevance:** The FDA has granted fast track designation (2019) for APR-246 alone<sup>14</sup> and breakthrough designation<sup>15</sup> (2020) in combination with azacitidine for myelodysplastic syndrome (MDS) patients harboring a TP53 mutation. Similar to APR-246, other investigational therapies aimed at restoring wild-type TP53 activity, as well as compounds that induce synthetic lethality are under clinical evaluation<sup>16,17</sup>. TP53 mutations confer poor prognosis in multiple blood cancers including acute myeloid leukemia (AML), MDS, myeloproliferative neoplasms (MPN), chronic lymphocytic leukemia (CLL),<sup>18,19,20,21</sup>. In mantle cell lymphoma, TP53 mutations are associated with poor prognosis when treated with conventional therapy including hematopoietic cell transplant<sup>22</sup>. Mono- and bi-allelic mutations in TP53 confer unique characteristics in MDS, with multi-hit patients also experiencing associations with complex karyotype, few co-occurring mutations, high-risk disease presentation, and predicted death and leukemic transformation independently of the IPSS-R staging system<sup>23</sup>.

### Tumor Mutational Burden

**Background:** Tumor mutational burden (TMB), also known as tumor mutational load (TML), is the count of somatic mutations in the DNA of cancer cells. TMB is determined by next-generation sequencing and is expressed as the number of mutations per megabase (mut/Mb) of DNA coding sequence<sup>24</sup>. Errors in DNA repair, including mutations in the POLE gene and in mismatch repair (MMR) genes, are associated with increased TMB<sup>25,26,27,28,29</sup>. High TMB is associated with increased neo-antigen burden and has been linked to response to immune checkpoint inhibitors (ICIs) that target the cytotoxic T lymphocyte antigen-4 (CTLA4), programmed death protein 1 (PD1), and programmed death-ligand 1 (PD-L1) inhibitors<sup>30,31,32,33</sup>.

**Alterations and prevalence:** In one study of over 100,000 tumor samples, the median TMB value was 3.6 mut/Mb although TMB values vary widely across cancers<sup>34</sup>. Certain childhood cancers, leukemia, glioblastoma, and neuroblastoma typically have low mutation burden and median TMB values <1 mut/Mb<sup>31,34</sup>. In comparison, cancers that experience genotoxic insults including skin cancer and lung cancer have higher median TMB values of approximately 10 mut/Mb<sup>31,34</sup>. For example, within non-small cell lung cancer (NSCLC), higher TMB was observed in former/current smokers (10.5 mut/Mb) relative to never smokers (0.6 mut/Mb)<sup>31,34,35</sup>. There is no consensus around the definition of high and low TMB that could be applied universally to all tumor types, instead multiple sources suggest that TMB status is a cancer type specific attribute<sup>34,36,37</sup>. In NSCLC, several studies have suggested establishing a threshold between low and high TMB of 10 +/- 1 mut/Mb<sup>38,39,40,41</sup>.

**Potential relevance:** ICIs stimulate a patient's own T-cells to kill tumors and have exhibited benefits in some patients. The first ICI to be approved by the FDA was ipilimumab (2011), an anti-CTLA4 antibody indicated for the treatment of metastatic melanoma. In 2014, anti-PD-1 antibodies nivolumab (2014) and pembrolizumab (2014) were subsequently approved, for the treatment of metastatic melanoma, and pembrolizumab also for advanced esophageal squamous cell carcinoma. In 2020, the indication for pembrolizumab<sup>42</sup> was expanded to include TMB-H (>= 10 mut/Mb) solid tumors that have progressed on prior therapy. Indications have been expanded for these ICIs to include several other cancer types including NSCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability (MSI)-High or mismatch repair deficient colorectal cancer, and hepatocellular carcinoma. Atezolizumab (2016), avelumab (2017), and durvalumab (2017), that target programmed death-ligand 1 (PD-L1) were subsequently approved by the FDA. However, the predictive biomarkers that underlie the clinical benefits of these approved immunotherapies, including TMB, are under active investigation. Several published studies including the CheckMate 586 and CheckMate 817 clinical trials have concluded that high TMB was associated with improved response to FDA approved checkpoint inhibitors<sup>39,43,44</sup>. In contrast, several previously promising trials have failed to show an improvement in survival outcomes between high and low TMB including CheckMate 227 (ipilimumab + nivolumab vs. chemotherapy), CheckMate 026 (nivolumab vs. chemotherapy), KEYNOTE 189 (pembrolizumab vs. chemotherapy), KEYNOTE 021 (pembrolizumab vs. pembrolizumab + chemotherapy), and Lung-MAP (nivolumab + ipilimumab vs. nivolumab). In response, suggestions to combine TMB score with PD-L1 expression as a way to increase the predictive power for patient stratification have been reported<sup>45</sup>. Nivolumab alone or in combination with ipilimumab is recommended for use in NSCLC with evidence of high TMB<sup>46</sup>. TMB score estimation is affected by the utilized assays, therefore efforts are underway to develop a standardized approach to calculate with the aim to support consistent reporting of TMB values across laboratories<sup>47,48,49,50</sup>.



## Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

### TP53 p.(R273H) c.818G>A

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
olaparib	×	○	×	×	● (II)
berzosertib	×	×	×	×	● (II)
talazoparib	×	×	×	×	● (II)
AT-406, nivolumab	×	×	×	×	● (I/II)
eprenetapopt, pembrolizumab	×	×	×	×	● (I/II)
HWH-340	×	×	×	×	● (I)
LY3143921	×	×	×	×	● (I)

### Tumor Mutational Burden

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
pembrolizumab	●	○	×	×	● (II)
ipilimumab + nivolumab	×	○	×	×	● (II)
nivolumab	×	○	×	×	● (II)
atezolizumab	×	×	×	×	● (II)
durvalumab, tremelimumab	×	×	×	×	● (II)
ipilimumab, nivolumab	×	×	×	×	● (II)
pembrolizumab, ipilimumab + nivolumab	×	×	×	×	● (II)
entinostat, nivolumab	×	×	×	×	● (I/II)
BAY1905254	×	×	×	×	● (I)
zimberelimab	×	×	×	×	● (I)

\* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.



## Relevant Therapy Details

### Current FDA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

FDA information is current as of 2020-10-14. For the most up-to-date information, search [www.fda.gov](http://www.fda.gov).

### Tumor Mutational Burden

#### ● pembrolizumab

Cancer type: Solid Tumor

Label as of: 2020-10-14

Variant class: Tumor Mutational Burden

#### Indications and usage:

KEYTRUDA® is a programmed death receptor-1 (PD-1)-blocking antibody indicated:

#### Melanoma

- for the treatment of patients with unresectable or metastatic melanoma.
- for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

#### Non-Small Cell Lung Cancer (NSCLC)

- in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS)  $\geq 1\%$ ] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
  - stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
  - metastatic.
- as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS  $\geq 1\%$ ) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA®.

#### Small Cell Lung Cancer (SCLC)

- for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.<sup>1</sup>

#### Head and Neck Squamous Cell Cancer (HNSCC)

- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS)  $\geq 1$ ] as determined by an FDA-approved test.
- as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

#### Classical Hodgkin Lymphoma (cHL)

- for the treatment of adult patients with relapsed or refractory cHL.
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.

#### Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

- for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.



## Tumor Mutational Burden (continued)

- Limitations of Use: KEYTRUDA® is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

### Urothelial Carcinoma

- for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS)  $\geq 10$ ] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.<sup>1</sup>
- for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

### Microsatellite Instability-High Cancer or Mismatch Repair Deficient Cancer

- for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
  - solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options,<sup>1</sup> or
  - colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.<sup>1</sup>
- Limitations of Use: The safety and effectiveness of KEYTRUDA® in pediatric patients with MSI-H central nervous system cancers have not been established.

### Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC)

- for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

### Gastric Cancer

- for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS)  $\geq 1$ ] as determined by an FDA-approved test, with disease progression on or after 2 or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.<sup>1</sup>

### Esophageal Cancer

- for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 [Combined Positive Score (CPS)  $\geq 10$ ] as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

### Cervical Cancer

- for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS)  $\geq 1$ ] as determined by an FDA-approved test.<sup>1</sup>

### Hepatocellular Carcinoma (HCC)

- for the treatment of patients with HCC who have been previously treated with sorafenib.<sup>1</sup>

### Merkel Cell Carcinoma (MCC)

- for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.<sup>1</sup>

### Renal Cell Carcinoma (RCC)

- in combination with axitinib, for the first-line treatment of patients with advanced RCC.

### Endometrial Carcinoma

- in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.<sup>1</sup>

### Tumor Mutational Burden-High (TMB-H) Cancer



## Tumor Mutational Burden (continued)

- for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [ $\geq 10$  mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.<sup>1</sup>
- Limitations of Use: The safety and effectiveness of KEYTRUDA® in pediatric patients with TMB-H central nervous system cancers have not been established.

### Cutaneous Squamous Cell Carcinoma (cSCC)

- for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

### Adult Indications: Additional Dosing Regimen of 400 mg Every 6 Weeks

- for use at an additional recommended dosage of 400 mg every 6 weeks for all approved adult indications.<sup>2</sup>

<sup>1</sup>This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

<sup>2</sup>This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.

### Reference:

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/125514s085lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf)





## Current NCCN Information

- ☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

NCCN information is current as of 2020-10-01. For the most up-to-date information, search [www.nccn.org](http://www.nccn.org).  
For NCCN International Adaptations & Translations, search [www.nccn.org/global/international\\_adaptations.aspx](http://www.nccn.org/global/international_adaptations.aspx).

### TP53 p.(R273H) c.818G>A

#### ☐ olaparib

Cancer type: Prostate Cancer

Variant class: HRR mutation

NCCN Recommendation category: 1

Population segment (Line of therapy):

- Castration Resistant Prostate Adenocarcinoma; M1; Prior therapy of abiraterone/enzalutamide (Second-line therapy) (Useful in certain circumstances)
- Castration Resistant Prostate Adenocarcinoma; M1 (Subsequent therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Prostate Cancer [Version 2.2020]

#### ☐ olaparib

Cancer type: Prostate Cancer

Variant class: HRR mutation

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Castration Resistant Prostate Adenocarcinoma; M1; Prior therapy of docetaxel (Second-line therapy) (Useful in certain circumstances)

Reference: NCCN Guidelines® - NCCN-Prostate Cancer [Version 2.2020]

## Tumor Mutational Burden

#### ☐ ipilimumab + nivolumab

Cancer type: Non-Small Cell Lung Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Non-Small Cell Lung Cancer; Emerging biomarker in metastatic disease (Not specified)

Reference: NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]



## Tumor Mutational Burden (continued)

### ○ nivolumab

**Cancer type:** Non-Small Cell Lung Cancer

**Variant class:** Tumor Mutational Burden

**NCCN Recommendation category:** 2A

**Population segment (Line of therapy):**

- Non-Small Cell Lung Cancer; Emerging biomarker in metastatic disease (Not specified)

**Reference:** NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]

### ○ pembrolizumab

**Cancer type:** Cervical Cancer

**Variant class:** Tumor Mutational Burden

**NCCN Recommendation category:** 2A

**Population segment (Line of therapy):**

- Recurrent or Metastatic Cervical Cancer; Progressed on prior treatment and does not have satisfactory alternative treatment options; Tumor mutational burden-high (TMB-H) [ $\geq 10$  mutations/megabase (mut/Mb)] as determined by an FDA-approved test (Second-line therapy) (Useful in Certain Circumstances)

**Reference:** NCCN Guidelines® - NCCN-Cervical Cancer [Version 2.2020]

### ○ pembrolizumab

**Cancer type:** Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Medullary Carcinoma, Thyroid Gland Papillary Carcinoma

**Variant class:** Tumor Mutational Burden

**NCCN Recommendation category:** 2A

**Population segment (Line of therapy):**

- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; Unresectable locoregional recurrent/persistent disease not amenable to RAI therapy (Not specified)
- Thyroid Gland Papillary, Follicular, Hurthle Cell Carcinoma; CNS or soft tissue or bone metastases not amenable to RAI therapy (Not specified)
- Thyroid Gland Medullary Carcinoma; Locoregional recurrent/persistent disease (Not specified) (Useful in Certain Circumstances)
- Thyroid Gland Medullary Carcinoma; Recurrent or persistent disease; Distant metastases; Asymptomatic, symptomatic or progression of disease (Not specified) (Useful in Certain Circumstances)
- Thyroid Gland Anaplastic Carcinoma; Metastatic (Not specified) (Useful in Certain Circumstances)

**Reference:** NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2020]



## Tumor Mutational Burden (continued)

### ○ pembrolizumab

Cancer type: Endometrial Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable or Metastatic Endometrial Carcinoma or Uterine Sarcoma; Progressed on prior treatment and does not have satisfactory alternative treatment options; Tumor mutational burden-high (TMB-H) [ $\geq 10$  mutations/megabase (mut/Mb)] as determined by an FDA-approved test (Not specified) (Useful in Certain Circumstances)

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 2.2020]

## Clinical Trials Summary

### TP53 p.(R273H) c.818G>A

NCT ID	Title	Phase
NCT04122625	A Dose-optimization, Exploratory Phase Ib/II Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143, When Given in Combination With the Anti-PD-1 Antibody Nivolumab in Patients With Specific Solid Tumors Who Have Progressed During or Immediately After Anti-PD-1/PD-L1 Treatment	I/II
NCT03096054	A Cancer Research UK (CR-UK) Phase I Trial of LY3143921 a Cdc7 Inhibitor in Adult Patients With Advanced Solid Tumours	I
NCT03718091	A Phase II Study of M6620 (VX-970) in Selected Solid Tumors	II
NCT02029001	A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors MOST: My own specific treatment	II
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial	II
NCT02401347	A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes Talazoparib Beyond BRCA (TBB) Trial	II
NCT04383938	Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies	I/II
NCT03415659	A Phase I, Open-label, Single-center, Single/Multiple-dose, Dose-escalation/Dose-expansion Clinical Study on Tolerance and Pharmacokinetics of HWH340 Tablet in Patients With Advanced Solid Tumors	I

## Tumor Mutational Burden

NCT ID	Title	Phase
NCT03767075	Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours	II



## Clinical Trials Summary (continued)

### Tumor Mutational Burden (continued)

NCT ID	Title	Phase
NCT02029001	A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors MOST: My own specific treatment	II
NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial	II
NCT03668119	A Randomized, Open-Label, Phase II Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	II
No NCT ID	A Multicenter Phase II Study Of Nivolumab Monotherapy In Recurrent And/Or Metastatic Gastrointestinal Cancer Patients With High Tumor Mutation Burden (TMB-H)	II
No NCT ID	TR Accompanied with the Study Titled A Multicenter Phase II Study of Nivolumab Monotherapy in Recurrent and/or Metastatic Gastrointestinal Cancer Patients with High Tumor Mutation Burden (TMB-H).	II
NCT02628067	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)	II
NCT02693535	Targeted Agent and Profiling Utilization Registry (TAPUR) Study	II
NCT03838042	INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents with Refractory High-risk Malignancies	I/II
NCT02992964	Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers	I/II
NCT03666273	An Open-label, Phase I, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the ILDR2 Function-blocking Antibody BAY1905254 in Patients With Advanced Solid Tumors	I
NCT04087018	A Phase Ib Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors	I



## Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:



## References

1. Muller et al. Mutant p53 in cancer: new functions and therapeutic opportunities. *Cancer Cell*. 2014 Mar 17;25(3):304-17. PMID: 24651012
2. Olivier et al. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol*. 2010 Jan;2(1):a001008. PMID: 20182602
3. Guha et al. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. *Cold Spring Harb Perspect Med*. 2017 Apr 3;7(4). PMID: 28270529
4. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012 May;2(5):401-4. PMID: 22588877
5. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet*. 2013 Oct;45(10):1113-20. PMID: 24071849
6. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 2012 Sep 27;489(7417):519-25. PMID: 22960745
7. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*. 2015 Jan 29;517(7536):576-82. PMID: 25631445
8. Campbell et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat. Genet*. 2016 Jun;48(6):607-16. PMID: 27158780
9. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. *Nature*. 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4. PMID: 28052061
10. Olivier et al. The IARC TP53 database: new online mutation analysis and recommendations to users. *Hum. Mutat*. 2002 Jun;19(6):607-14. PMID: 12007217
11. Rivlin et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. *Genes Cancer*. 2011 Apr;2(4):466-74. PMID: 21779514
12. Petitjean et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. *Oncogene*. 2007 Apr 2;26(15):2157-65. PMID: 17401424
13. Soussi et al. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. *Hum. Mutat*. 2014 Jun;35(6):766-78. PMID: 24729566
14. <https://www.aprea.com/news/aprea-therapeutics-receives-fda-fast-track-designation-and-orphan-drug-designation-for-apr-246-for-the-treatment-of-myelodysplastic-syndromes-mds/>. <https://www.aprea.com/news/aprea-therapeutics-receives-fda-fast-track-designation-and-orphan-drug-designation-for-apr-246-for-the-treatment-of-myelodysplastic-syndromes-mds/>
15. <http://vp280.alertir.com/en/pressreleases/karolinska-development%27s-portfolio-company-aprea-therapeutics-receives-fda-breakthrough-therapy-designation-1769167>
16. Parrales et al. Targeting Oncogenic Mutant p53 for Cancer Therapy. *Front Oncol*. 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015. PMID: 26732534
17. Zhao et al. Molecularly targeted therapies for p53-mutant cancers. *Cell. Mol. Life Sci*. 2017 Nov;74(22):4171-4187. PMID: 28643165
18. NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 4.2020]
19. NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 1.2021]
20. NCCN Guidelines® - NCCN-Myeloproliferative Neoplasms [Version 1.2020]
21. NCCN Guidelines® - NCCN-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Version 1.2021]
22. NCCN Guidelines® - NCCN-B-Cell Lymphomas [Version 4.2020]
23. Bernard et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat. Med*. 2020 Aug 3. PMID: 32747829
24. Yuan et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 4:3. PMID: 26788324
25. Temko et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. *J. Pathol*. 2018 Jul;245(3):283-296. PMID: 29604063



## References (continued)

26. Mehnert et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. 126(6):2334-40. PMID: 27159395
27. Bouffet et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J. Clin. Oncol. 2016 Jul 1;34(19):2206-11. PMID: 27001570
28. Humphris et al. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 Jan;152(1):68-74.e2. PMID: 27856273
29. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017;2017. PMID: 29850653
30. Snyder et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014 Dec 4;371(23):2189-2199. PMID: 25409260
31. Alexandrov et al. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415-21. PMID: 23945592
32. Rizvi et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3;348(6230):124-8. PMID: 25765070
33. Van et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 Oct 9;350(6257):207-211. PMID: 26359337
34. Chalmers et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. 9:34. PMID: 28420421
35. Govindan et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012 Sep 14;150(6):1121-34. PMID:22980976
36. Endris et al. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int. J. Cancer. 2019 May 1;144(9):2303-2312. PMID: 30446996
37. Meléndez et al. Methods of measurement for tumor mutational burden in tumor tissue. Transl Lung Cancer Res. 2018 Dec;7(6):661-667. PMID: 30505710
38. Hellmann et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N. Engl. J. Med. 2018 May 31;378(22):2093-2104. PMID: 29658845
39. Ready et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J. Clin. Oncol. 2019 Apr 20;37(12):992-1000. PMID: 30785829
40. Alborelli et al. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. J. Pathol. 2020 Jan;250(1):19-29. PMID: 31471895
41. Heeke et al. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers (Basel). 2019 Aug 29;11(9). PMID: 31470674
42. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/125514s085lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf)
43. F. et al. CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC. Volume 14, Issue 10, Supplement, Pages S214–S215. Abstract OA04.02
44. Zhu et al. Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. Front Oncol, 9:1161, 04 Nov 2019. PMID: 31258479
45. Castellanos et al. Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC. Journal of Clinical Oncology 37, no. 15\_suppl (May 20, 2019) 2630-2630. Abstract 2630
46. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 8.2020]
47. <https://www.focr.org/tmb>
48. <http://www.iqnpaath.org/category/tmb>
49. Stenzinger et al. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer. 2019 Aug;58(8):578-588. PMID: 30664300
50. Merino et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020 Mar;8(1). PMID: 32217756